Şunu aradınız:: biotechnology (Hollandaca - İspanyolca)

abbott biotechnology deutschland gmbh
153 responsable de la fabricación:

abbott biotechnology deutschland gmbh max-planck-ring 2 es
max-planck-ring 2 d-65205 wiesbaden alemania na

roche diagnostics gmbh, pharma biotechnology production nonnenwald 2 82372 penzberg duitsland
roche diagnostics gmbh, pharma biotechnology production nonnenwald 2 82372 penzberg alemania

abbott biotechnology deutschland gmbh max-planck-ring 2 d-65205 wiesbaden duitsland
abbott biotechnology deutschland gmbh max-planck-ring 2 d-65205 wiesbaden alemania

abbott biotechnology deutschland gmbh er max-planck-ring 2 ng d-65205 wiesbaden duitsland t la
na responsable de la fabrica ción abbott biotechnology deutschland gmbh max-planck-ring 2

concept-rapporten concept paper on gene therapy concept paper on the development of a cpmp guideline on comparability of biotechnology-derived products
concept paper on gene therapy concept paper on the development of a cpmp guideline on comparability of biotechnology- d e r ived products

de voor de veiligheidscontrole van bt11 gebruikte methoden waren ook in overeenstemming met de onlangs door de wetenschappelijke stuurgroep opgestelde richtsnoeren voor de beoordeling van ggo's en genetische gemodificeerde levensmiddelen en diervoeders en met de codex principles and guidelines on foods derived from biotechnology.
la metodología utilizada para evaluar la seguridad del bt11 era, asimismo, conforme con las directrices recientemente elaboradas por el comité director científico sobre la evaluación de los organismos modificados genéticamente (omg), los alimentos mg y los piensos mg, y con los principios y las directrices del codex sobre alimentos derivados de la biotecnología.

63) note for guidance on photosafety testing; points to consider document on the need for assessment of reproductive toxicity in the development of human insulin analogues discussion paper on environmental risk assessments of non-gmo containing medicinal products for human use non-clinical documentation of medicinal products with ‘ well-established use’ note for guidance on the need for non-clinical testing of pharmaceuticals in juvenile animals discussion paper on the non-clinical safety studies to support single low dose clinical screening studies in man note for guidance on specification limits for residues for heavy metal catalysts in medicinal products points to consider on xenogeneic cell therapy note for guidance on comparability of biotechnology products pre-clinical and clinical issues points to consider on the assessment of the potential for qt interval prolongation by non-cardiovascular medicinal products note for guidance on risk assessment of medicinal products on human reproductive and development toxicities: from data to labelling
63) note for guidance on photosafety testing points to consider document on the need for assessment of reproductive toxicity of human insulin analogues discussion paper on environmental risk assessments of non-gmo containing medicinal products for human use non-clinical documentation of medicinal products with ‘ well-established use’ note for guidance on the need for non-clinical testing of pharmaceuticals in juvenile animals discussion paper on the non-clinical safety studies to support single low dose clinical screening studies in man note for guidance on specification limits for residues for heavy metal catalysts in medicinal products points to consider on xenogeneic cell therapy note for guidance on comparability of biotechnology products pre-clinical and clinical issues points to consider on the assessment of the potential for qt interval prolongation by non-cardiovascular medicinal products note for guidance on risk assessment of medicinal products on human reproductive and development toxicities: from data to labelling